Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FE203799 GLP-2 analogue · 1 trial · 1 indication
Adverse events (AEs) as assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| FE203799 5 mg | EXPERIMENTAL | FE203799 GLP-2 analogue, once weekly, subcutaneous administration |
| Placebo | PLACEBO_COMPARATOR | Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration |
| FE203799 10 mg | OTHER | FE203799 GLP-2 analogue, once weekly, subcutaneous administration |
| Name | Type | Description |
|---|---|---|
| FE203799 GLP-2 analogue | DRUG | FE203799 5 mg subQ once weekly |
| FE203799 Placebo GLP-2 analogue | DRUG | Placebo subQ once weekly |
Inclusion Criteria 1. Males and females with SBS secondary to surgical resection of small intestine 2. 18-80 years of age 3. Body Mass Index (BMI) between 16.0 and 32.0 4. Patients with a jejuno- or ileostomy and a faecal wet weight excretion of at least 1500 g/day, as recorded within the last 18 m...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 4 | PHASE3 | Teduglutide |
| Jaguar Health, Inc. | JAGX | 1 | PHASE2 | Crofelemer for |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | - | Undisclosed |
FE203799 GLP-2 analogue is an investigational small molecule being developed for Short Bowel Syndrome, a gastrointestinal condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
FE203799 GLP-2 analogue is a GLP-2 analogue, meaning it is designed to mimic the activity of glucagon-like peptide-2, a hormone involved in intestinal growth and function. This mechanism is being studied for its potential to help patients with Short Bowel Syndrome.
FE203799 GLP-2 analogue is being developed by Ironwood Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IRWD.
FE203799 GLP-2 analogue is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Its Phase 1 trial has been completed.
FE203799 GLP-2 analogue has one completed Phase 1 trial, NCT03415594, titled 'Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support.' This randomized, double-blind, placebo-controlled study enrolled 8 participants in Denmark.